Clinical uses of pegylated pharmaceuticals in oncology

Cancer Treatment Reviews

Volumn 28, Issue SUPPL. A, 2002, Pages 7-11

  Crawford, Jeffrey ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Oncology; Pegfilgrastim; Peginterferon alpha 2a; Pegylated liposomal doxorubicin; Pegylation

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOME; MACROGOL; NAVELBINE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG UTILIZATION; HUMAN; KIDNEY CARCINOMA; NEUTROPENIA; PHARMACOKINETICS; SOLID TUMOR;

EID: 0036087486     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)80003-2     Document Type: Article

References (22)

1. Pegylation: Engineering improved pharmaceuticals for enhanced therapy
2. Filgrastim: A review of its pharmacological properties and therapeutic efficacy in neutropenia
3. Filgrastim (r-metHuG-CSF): The first 10 years
4. Current status of pegylated G-CSF (SD/01) in chemotherapy-induced neutropenia
5. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans
6. Novel effects with polyethylene glycol-modified pharmaceuticals
7. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy
8. A randomized, double-blind, phase 3 study evaluating fixed-dose, once-per-cycle pegylated filgrastim (SD/01) vs daily filgrastim to support chemotherapy for breast cancer
9. Blinded, randomized, multicenter trial to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk Stage II or Stage III/IV breast cancer
10. Polyethylene glycol liposomal doxorubicin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma
11. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: Rationale for use in solid tumours
12. Retrospective analysis of pegylated liposomal doxorubicin and cardiotoxicity
13. Pegylated doxorubicin (Doxo-P) in the treatment of aggressive diffuse large cell lymphoma (DLCL)
14. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
15. Phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxane-containing chemotherapy regimen
16. Long-term follow-up of pegylated liposomal doxorubicin (Caelyx): A well tolerated and effective agent in advanced hepatocellular carcinoma (HCC)
17. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma
18. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)
19. Phase II trial of branched pegylated (40kDa) interferon α-2a for patients with advanced renal cell carcinoma (RCC)
20. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
21. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C
22. Peginterferon alfa-2a in patients with chronic hepatitis C